C/EBPa is a key transcription factor indispensable for the onset of gluconeogenesis in perinatal liver. However, C/ EBPa was already expressed in fetal liver, suggesting that the expression of C/EBPa alone does not account for the dramatic increase of the expression of metabolic genes, and hence an additional factor(s) is expected to function cooperatively with C/EBPa in perinatal liver. We show here that expression of Foxo1 was sharply increased in the perinatal liver and augmented C/EBPa-dependent transcription. Foxo1 bound C/EBPa via its forkhead domain, and Foxo1 bound to the promoter of a gluconeogenic gene, phosphoenolpyruvate carboxykinase (PEPCK), in a C/ EBPa-dependent manner in vivo. Insulin inhibited the expression of PEPCK in a culture of fetal liver cells, and also the C/EBPa-dependent transcription enhanced by Foxo1. These results indicate that Foxo1 regulates gluconeogenesis cooperatively with C/EBPa, and also links insulin signaling to C/EBPa during liver development.
Introduction
During mammalian development, characteristics of the liver change drastically from a major hematopoietic tissue in fetus toward a central metabolic tissue in adult (Girard, 1990) . While nutrients are provided from mother via the placenta in prenatal stage, nutritional supplies from mother stop abruptly after birth. Thus, newborns have to survive by their own metabolic functions immediately after birth, and the liver changes gene expression dramatically during the perinatal stage for the adaptation, which requires the changes in transcription factors (Schrem et al, 2004) . It is well established that C/EBPa is an essential factor for glucose metabolism during perinatal stage. In C/EBPa-deficient mice, expression of gluconeogenic genes is blunted and the blood glucose level is significantly low, leading to neonatal death Wang et al, 1995) . The blood glucose level is important for energy homeostasis and is strictly regulated by insulin. In fetus at a late gestational stage, the plasma insulin level is high and gluconeogenic genes are suppressed, whereas it decreases rapidly after birth, resulting in upregulation of gluconeogenic enzymes (Blazquez et al, 1970; Croniger et al, 1997) . Although a variety of extracellular signals, including insulin, have been suggested to regulate C/ EBPa activity, the precise mechanism how insulin regulates C/EBPa activity is not fully elucidated.
Foxo1 is a member of the forkhead family transcription factors and regulates glucose metabolism in the adult liver (Puigserver et al, 2003; Accili and Arden, 2004) . Foxo1 regulates the expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) genes by direct binding to its target DNA sequence and also through the interaction with nuclear receptors. Foxo1 activity is regulated by phosphorylation and acetylation. Insulin induces phosphorylation of Foxo1 through the PI3K-Akt signaling pathway. Phosphorylated Foxo1 is excluded from the nucleus, and thereby its transcriptional activity is attenuated (Brunet et al, 1999; Kops et al, 1999) .
Dramatic expression of metabolic enzymes just before birth requires C/EBPa. However, the underlying mechanism for the drastic enhancement of gene expression is not well understood. We found that C/EBPa was already expressed in fetal liver, suggesting that there is a mechanism that regulates the C/EBPa function. We show here that Foxo1 enhances C/ EBPa-dependent transcription in the developing liver cells, through the direct interaction between these molecules.
Results

Expression of C/EBPa during liver development
As C/EBPa plays a key role for expression of various metabolic enzymes at a perinatal stage , we first examined the expression of C/EBPa during liver development, and revealed that it was already expressed in E14.5 liver and was not changed drastically in the E18.5 and neonatal liver (Figure 1A) . Consistently with the in vivo result, the expression of C/EBPa mRNA was not changed in fetal hepatocytes culture, in which they differentiated ( Figure 1A ; Kamiya et al, 1999) . As C/EBPa is regulated translationally, we also examined the isoforms (p42 and p30) of C/EBPa protein (Ossipow et al, 1993; Calkhoven et al, 2000) . The levels of isoforms were not changed during liver development in vivo and also in fetal hepatocyte culture, in which hepatocyte differentiation was induced ( Figure 1B) . These results suggest that there is a post-translational regulatory mechanism that enhances C/EBPa activity in perinatal liver.
Insulin regulation of metabolic enzymes during liver maturation
Insulin is a critical regulator for glucose metabolism in the liver (Saltiel and Kahn, 2001) . Insulin secreted from the pancreas in response to the blood glucose level represses gluconeogenesis and enhances glycolysis in the adult liver and muscle (Saltiel and Kahn, 2001) . We examined the effect of insulin on the expression of gluconeogenic genes in a primary culture of fetal liver cells, by quantitative PCR (qPCR). Expression of C/EBPa and Foxo1 was not affected by insulin. While PEPCK and G6Pase were expressed in differentiated fetal liver cells in the presence of insulin, depletion of insulin from the culture at day 3 enhanced expression of PEPCK and G6Pase compared with the standard culture condition containing insulin throughout the culture, indicating that insulin negatively regulates gluconeogenesis as is known in adult liver ( Figure 1C) . In contrast to wild-type cells, PEPCK was not expressed in C/EBPa KO liver culture, and insulin depletion did not affect the expression (Supplementary Figure S1) . Interestingly, the expression of another C/EBPa target, glycogen synthase (Gys2), was expressed in the liver from E14 to adult and was not affected by insulin ( Figure 1C ).
Expression of Foxo1 during the liver development
On the basis of the observation that insulin affects gluconeogenesis, we assumed that Foxo1, a target of insulin signaling, might be involved in gluconeogenesis in fetal as well as in adult liver. To investigate whether Foxo1 plays a role for liver development, we first examined the expression of Foxo1 during liver development. Foxo1 mRNA expression in liver was barely detectable at E14.5 and dramatically increased at E18.5 (Figure 2A ). Furthermore, we examined Foxo1 protein in nuclear extracts. Foxo1 was abundantly present in the nuclear extract of neonate liver, but only small amount was detected in the nuclear extracts from E14.5 and adult liver ( Figure 2B ). In spite of the abundant presence of Foxo1 protein in neonatal liver, phosphorylated Foxo1 protein in neonatal liver was comparable to that in E18 liver and Foxo1 protein was mostly in the nucleus ( Figure 2B ).
Glucocorticoid is also required for liver maturation, especially for the expression of gluconeogenic genes in vivo and also in vitro (Cole et al, 1995) . As glucocorticoid has been shown to induce Foxo1 expression in the muscle (Furuyama et al, 2003) , we evaluated the effect of glucocorticoid on Foxo1 expression in the liver. E14.5 liver cells were cultured with or without a glucocorticoid agonist, dexamethasone (Dex). As shown in Figure 2C , Dex augmented the expression of Foxo1 in the primary hepatocytes. On the other hand, insulin did not affect expression of Foxo1 in the hepatocyte culture ( Figure 1C ). Foxo1 is transcriptionally active in the nucleus and is inactivated by the exclusion from the nucleus by phosphorylation (Brunet et al, 1999; Kops et al, 1999) . We therefore examined the localization of Foxo1 protein by immunohistochemistry. In the neonate liver, Foxo1 protein was located in the nucleus as well as cytoplasm ( Figure 2D ), as confirmed by the Western blot (Supplementary Figure S2) , suggesting that Foxo1 was actively involved in gene expression. We then evaluated the effect of Foxo1 on the expression of PEPCK and G6Pase during maturation. Fetal liver cells were infected with retrovirus expressing a dominant-negative form (D256) or a constitutively active form (3A) of Foxo1, and their effect was examined. The expression of each mutant was examined by Western blotting using antibody against Foxo1 N-terminal domain (Supplementary Figure S3) and infection efficiency was estimated to be B50%, by FACS analysis (Supplementary Figure S3) . The expression of PEPCK and G6Pase was repressed by D256 Foxo1 and enhanced by 3A Foxo1 ( Figure 2E ). Next, we employed shRNA to test the involvement of C/EBPa and Foxo1 in gluconeogenic gene expression. While suppression of C/EBPa and Foxo1 by shRNAs was incomplete, expression of both PEPCK and G6Pase was significantly reduced (data not shown). These results from in vivo and in vitro studies implicate Foxo1 to the expression of the gluconeogenic genes in the perinatal liver.
Enhancement of C/EBPa-dependent transcriptional activation by Foxo1
Based on these results, we reasoned that Foxo1 would be involved in perinatal gluconeogenesis, and it might cooperatively function with C/EBPa. To test if Foxo1 is involved in C/ EBPa function, we first examined the effects of Foxo1 and C/ EBPa on the PEPCK promoter by employing luciferase reporter assays. Foxo1 and C/EBPa activated the PEPCK promoter as reported previously, and coexpression of these two proteins further enhanced promoter activity ( Figure 3A ). To analyze the cooperative function of C/EBPa and Foxo1 in detail, we used a synthetic C/EBPa response element (aRE). While Foxo1 alone failed to activate transcription from aRE, Foxo1 augmented C/EBPa-dependent transcription in a dosedependent manner, whereas the D256 mutant of Foxo1 that lacks transcriptional activity on its cognate response element failed to enhance C/EBPa activity ( Figure 3B ). PGC-1a, a coactivator of Foxo1, enhanced transcription from the aRE in the presence of Foxo1 and C/EBPa, and insulin suppressed the transcriptional enhancement by Foxo1 ( Figure 3C and D). These results indicate that Foxo1 regulates transcriptional activity of C/EBPa during liver development, which is regulated by insulin. The results also suggest that Foxo1 and PGC1a not only cooperate on the Foxo1 binding element but also on the C/EBPa binding element.
Foxo1 directly interacts with C/EBPa via the forkhead domain
We considered the possibility that cooperation between Foxo1 and C/EBPa is through their physical interaction. To test this idea, co-immunoprecipitation experiments were performed using neonate liver. Foxo1 was co-immunoprecipitated with C/EBPa ( Figure 4A ). However, such an interac-
GAPDH
E14
E18 Neo tion was not detected in the E14.5 liver (data not shown). To demonstrate direct binding between the two proteins, we expressed GST-Foxo1 fusion protein in Escherichia coli. Fusion protein was purified and mixed with HA-C/EBPa produced by in vitro translation. C/EBPa was pulled down by GST-Foxo1, indicating that these two protein physically interact ( Figure 4B ). We then delineated the domains responsible for the interaction between these two proteins ( Figure  4C and D). Full-length Foxo1 (WT) protein efficiently coimmunoprecipitated C/EBPa and the mutant containing the N-terminal portion, that is, D256, also co-immunoprecipitated C/EBPa. However, mutant lacking the N-terminal domain, DN, failed to immunoprecipitate C/EBPa. Thus, Nterminal portion of Foxo1 is necessary and sufficient for the interaction with C/EBPa. We further examined the interaction between the two proteins using point mutants of Foxo1 proteins. 3A Foxo1 is a constitutively active mutant, in which three amino-acid residues responsible for phosphorylation are replaced with alanine. The WH mutant has aminoacid substitutions, that is, substitution of the tryptophan residue at 206 to glycine (W206G) and substitution of the histidine residue at 212 to proline (H212P), in the helix 3 in the DNA binding region, and is devoid of DNA binding to and transactivation from the Foxo1 responsive DNA element (Schmoll et al, 2000) . The 3A mutant bound C/EBPa as efficiently as WT Foxo1. Interestingly, WH mutant did not bind C/EBPa and single substitution mutants, W206G Foxo1 and H212P Foxo1, also failed to bind C/EBPa ( Figure 4E ). These results indicate that the helix 3 in the DNA binding region of Foxo1 is required for the interaction between the two proteins (Lai et al, 1993; Schmoll et al, 2000) . We then examined acetylation mutants of Foxo1 because it was reported that CBP-dependent acetylation and Sirt1-dependent deacetylation modulate transcriptional activity of Foxo1 by regulating its DNA binding (Matsuzaki et al, 2005) . To test this possibility, we utilized 3KA and 3KR mutants, in which three lysine residues (K242, K245 and K262) were replaced with alanine and arginine, respectively. They are considered to mimic an acetylated and non-acetylated form of Foxo1, respectively. Both 3KA and 3KR bound C/EBPa Figure 4F ). These mutant enhanced C/EBPa dependent transcription comparably ( Figure 3E and F). These results suggest that the helix 3 in the forkhead domain is required for the binding to C/EBPa, but acetylation of the three lysine residues of Foxo1 and the DNA binding activity of Foxo1 did not have a major impact on the interaction between Foxo1 and C/EBPa, though the helix 3 is necessary for DNA binding (Schmoll et al, 2000) . Next we mapped the domain of C/EBPa responsible for binding to Foxo1 and found that that the C-terminal domain of C/EBPa has a strong binding ability to the N-terminal portion of Foxo1 ( Figure 5 ).
C/EBPa-Foxo1 complex on target DNA
To test whether the interaction between C/EBPa and Foxo1 occurs on DNA, we employed avidin-biotin-conjugated DNA binding (ABCD) assay. C/EBPa alone efficiently bound to aRE and the binding of C/EBPa to the aRE was inhibited by coexpression of a dominant-negative form of C/EBPa, showing specific binding of C/EBPa to the beads (data not shown). Whereas Foxo1 alone did not bind this DNA, Foxo1 was efficiently precipitated together with C/EBPa by the aREconjugated magnetic beads when Foxo1 was coexpressed with C/EBPa ( Figure 6A ). However, unrelated DNA sequence failed to precipitate these proteins. These results indicate that binding of Foxo1 to aRE is achieved through the interaction with C/EBPa.
To verify the recruitment of C/EBPa and Foxo1 to the promoter in vivo, we utilized the chromatin immunoprecipitation (ChIP) assay. Cell lysates prepared from neonate liver were used for ChIP assays to test if endogenous proteins were recruited to the PEPCK promoter in vivo. We immunoprecipitated the cell lysate with antibodies against Foxo1, C/EBPa and acetylated histone H3, and immunoprecipitates were subjected to PCR using primers to amplify the DNA fragment (À210 to þ 67 nucleotide) of the PEPCK promoter. These antibodies immunoprecipitated the promoter fragment from neonatal liver ( Figure 6B ), but not from E14.5 liver (data not shown), indicating that both Foxo1 and C/EBPa were recruited to the promoter.
To address whether the recruitment of Foxo1 to the promoter depends on the presence of C/EBPa, we performed ChIP assays using C/EBPa-deficient liver cells. Neither C/ EBPa nor Foxo1 was recruited to the PEPCK promoter in C/ EBPa-deficient cells ( Figure 6B ). To exclude effects of C/EBPa on hepatocyte development, we knocked down C/EBPa expression in wild-type cells by shRNA and examined occupancy of Foxo1 on the PEPCK promoter ( Figure 6C ). The results were consistent with the C/EBPa knockout cells. These results indicate that C/EBPa is necessary for the recruitment of Foxo1 to the PEPCK promoter.
Discussion
As the C/EBPa expression alone cannot account for the expression of metabolic genes in the perinatal liver and in primary cultured hepatocytes, an additional factor(s) is necessary for the dramatic increase of metabolic genes in the perinatal liver (Figure 1 ). We show that Foxo1 expression in the liver was abruptly upregulated before birth, and that Foxo1 augmented C/EBPa-dependent transcription through direct interaction. As the expression of gluconeogenic genes is regulated cooperatively by multiple transcription factors, including C/EBPs, CREB, HNFs, GR, PPARs and AP-1, it is rather difficult to dissect their complex interactions in vivo (Desvergne et al, 2006) . Nevertheless we provide several lines of evidence that Foxo1 participates in the C/EBPadependent transcription of gluconeogenic genes in the perinatal liver, and PGC-1a also participates in this coregulation. Immunoprecipitation demonstrated the direct interaction between C/EBPa and Foxo1. ABCD assays revealed that Foxo1 binds to the aRE only when it is coexpressed with C/EBPa, and ChIP assays also showed that Foxo1 is recruited to the PEPCK promoter only in the presence of C/EBPa. Although somewhat controversial results were reported on the function of C/EBPa for glucose metabolism in adult liver (Lee et al, 1997; Inoue et al, 2004; Qiao et al, 2006) , it is considered that C/EBPa also plays an important role for glucose metabolism in adult liver. The C/EBPa-Foxo1 complex may exhibit different functions, depending on cellular context, for example, fetal versus adult liver. Although both C/EBPa and Foxo1 were shown to have a role in growth arrest, it is unlikely that they cooperate in this case, because growth arrest by C/EBPa does not require the Foxo1 interaction domain.
As the DNA binding domain of Foxo1 was required for the interaction with C/EBPa ( Figure 4C and D) , we examined acetylation mutants of Foxo1 that modulate DNA binding (Matsuzaki et al, 2005) . Mutants considered to mimic an acetylated and non-acetylated form of Foxo1, bound to C/ EBPa, there was no significant difference in C/EBPa-dependent transcriptional activity between these mutants compared with wild type Foxo1 ( Figures 3E, F and 4F ). However, as these results were obtained by overexpression experiments, it remains possible that in the physiological condition, acetylation of Foxo1 may affect the cooperation with C/EBPa. Because the third helix of Foxo1 was required for C/EBPa binding and is conserved among the Forkhead family members (Lai et al, 1993) , the family members other than Foxo1 may also interact with C/EBPa. In fact, we found that Foxo3 was also expressed in E18.5 liver and interacted with C/EBPa (data not shown). The C-terminal region of C/ EBPa was shown to interact with Foxo1, and this region is relatively conserved among the C/EBP family members ( Figure 5 ). C/EBPb also bound to Foxo1 (data not shown), suggesting that C/EBPb may also function together with Foxo1 to regulate gene expression. In fact, C/EBPb was reported to play a role for glucose metabolism in the perinatal liver; although some of C/EBPb KO mice were viable, all C/ EBPb KO mice in the context of C/EBPa þ /À background died immediately after birth, because of impaired glucose homeostasis, similar to C/EBPa KO mice (Begay et al, 2004) . Among various liver enzymes, those involved in glucose metabolism are subject to insulin regulation in adult liver. Insulin regulates the blood glucose level by repressing gluconeogenesis and stimulating glycolysis (Saltiel and Kahn, 2001 ). While the plasma insulin level is high and gluconeogenic genes are suppressed in fetus, it rapidly decreases and gluconeogenic genes are upregulated after birth (Blazquez et al, 1970; Girard et al, 1992) . Foxo1 is phosphorylated by insulin through the PI3 kinase/Akt pathway, and the phosphorylated Foxo1 is excluded from the nucleus, resulting in the attenuation of its transcription activity (Brunet et al, 1999; Kops et al, 1999) . Consistently, we show that insulin suppressed expression of PEPCK and G6Pase in primary culture of fetal liver cells and that insulin also inhibited C/ EBPa-dependent transcription enhanced by Foxo1. In contrast to PEPCK and G6Pase that are sharply upregulated at the perinatal stage and subject to insulin regulation, expression of the other C/EBPa target genes, Gys2 and glucokinase (Gck), which are involved in glycogen synthesis and glycolysis, were not altered by insulin in the fetal liver. Interestingly, Gys2 is constantly expressed in the liver from E14 to adult, and Gck expression in E14 and neonate liver as well as fetal liver cells induced to differentiate in vitro was very low, that is, undetectable by Northern blot (data not shown). Thus, while there are several types of gene regulation in C/EBPa target genes, at least two key enzymes for gluconeogenesis are subject to insulin regulation via Foxo1 and C/EBPa. Although both insulin and C/EBPa have been known to regulate gluconeogenesis, the link between insulin and C/ EBPa has not been understood. Our results provide evidence for the first time that Foxo1 regulates C/EBPa function and links the insulin signaling to C/EBPa in the perinatal liver.
Materials and methods
Plasmids and antibodies C/EBPa cDNA was cloned by PCR into pcDNA3 vector (Invitrogen), based on the reported sequence. C/EBPa response element (aRE; CGCGTATTGGCCAATATTGG CCAATCTCGA) and PEPCK promoter (À450BÀ1) were inserted into pGL3 vector (Promega). The 3xIRS Foxo1 response element was described previously (Daitoku et al, 2004) . Mouse Foxo1 mutants, 3A Foxo1 and WH Foxo1 were described previously (Daitoku et al, 2004) , and a series of mutants were generated on the basis of these constructs. Antibodies used in this study are the following: anti-C/EBPa (14AA, SantaCruz), antiFoxo1 (H-128, N-18, SantaCruz, and C3; Daitoku et al, 2003) , antiphospho-Foxo1 (#9461, Cell Signaling Technology), anti-HA tag (12CA5, Roche), anti-Flag tag (SIGMA), anti-acetylated histone H3 (Upstate), anti-actin (I-19, SantaCruz), anti-tubulin (T5168, SIGMA) and anti-TBP (N-12, SantaCruz). shRNA for Foxo1 and C/EBPa were of Expression Arrest Mouse retroviral shRNAmir (Open Biosystems).
Cell culture, transfection, and luciferase assays Fetal liver cells were cultured as reported previously (Kamiya et al, 1999) . Briefly, E14.5 fetal liver cells were dissected in the liver perfusion medium (Invitrogen), and a single cell suspension was obtained by collagenase digestion and seeded on the gelatin-coated dishes. Cells were maintained in the presence of OSM, Dex and insulin throughout the culture, unless otherwise indicated. 293T cells were maintained in DMEM with 10%FCS.
Transfection was performed by using the Lipofectamine and plus reagent, according to the manufacturer's instruction (Invitrogen). Luciferase assay was performed according to the manufacturer's instruction (Promega). Each experiment was performed in triplicate.
All experiments using cultured fetal liver cells were performed with at least three different cell preparations.
C/EBPa KO mice were generously provided by Dr Darlington (Baylor College of Medicine). Pups obtained by crossing of heterozygotes were collected, and at least three different pups were used for analysis. Genotypes were determined by PCR using following primers: for wild-type allele, 5 0 -AGACCAGAAAGCT GAGTTGTGAGTT-3 0 and 5 0 -CAAAACCAAAACAAAACAAAAGACC-3 0 ; for mutant allele, 5 0 -ACGACGGGCGTTCCTTGCGCAGCTGTG-3 0 and 5 0 -TCAGAAGAACTCGTCAAGAAGGCGATA-3.
qPCR
Total RNA was prepared from livers by Trizol (Invitrogen), and was further purified using the High Pure RNA isolation kit (Roche). Reverse transcription was performed by using the QuantiTect Reverse Transcription kit (Qiagen) and qPCR analysis was performed by using TaqMan Gene Expression Assays (Applied Biosystems), using GeneAmp 5700 Sequence Detection System (Applied Biosystems). Each experiment was performed in triplicate, and with at least two different RNA preparations.
Immunohistochemistry
Neonate liver was embedded in 4% carboxymethyl cellulose gel and sectioned. Sections were fixed with 4% paraformaldehyde and stained with anti-Foxo1 antibody. Alexa Fluor 488-conjugated antirabbit IgG antibody was used as the secondary antibody. Nuclei were stained with propidium iodide. Nuclear and cytosolic extraction Nuclear and cytosolic extracts were prepared by the standard procedure (Timchenko et al, 1999) .
Immunoprecipitation and Western blotting
Neonatal liver cells or 293T cells transfected with expression vectors for a series of Flag-tagged Foxo1 mutants with HA-tagged C/EBPa were lysed with lysis buffer (10 mM Hepes-KOH (pH7.9), 100 mM KCl, 0.1% NP-40, 0.5 mM EDTA, protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 5 mg/ml aprotinin, and 5 mg/ml leupeptin)) and incubated with anti-C/EBPa antibody or anti-Flagtag antibody-linked agarose beads. C/EBPa antibody was immunoprecipitated with protein G agarose beads. The immunoprecipitates were washed with lysis buffer, and subjected to SDS-PAGE, and immunoblotted using antibodies against Foxo1 or HA-tag.
GST pull-down assay GST-Foxo1 fusion protein was expressed in BL21(DE3) strain of E. coli by using the pGEX-5X-1 vector. HA-tagged C/EBPa protein was prepared using the TnT reticulocyte lysate system (Promega), according to the manufacturer's instruction. GST fusion protein was purified with glutathione sepharose 4B (GE healthcare). Purified glutathione sepharose -bound-GST-Foxo1 was mixed with in vitro translated HA-C/EBPa protein in lysis buffer. The glutathione sepharose beads were washed three times with lysis buffer, and subjected to SDS-PAGE, and immunoblotted using antibodies against HA tag.
ABCD assay
The DNA-avidin beads complex was prepared by adding the annealed biotinylated DNA to 30 ml of the streptavidin-conjugated magnetic beads (iMag Streptavidin Particles Plus-DM, BD), and mixed by a mixer overnight and washed with TE to eliminate unbound DNA. To prepare cell lysates, cultured cells were lysed with lysis buffer and the insoluble materials were removed by centrifugation. The supernatant was incubated with DNA-avidin beads and 50 mg of poly(dI-dC). After 20-60 min at 41C, beads were collected by magnet and washed with lysis buffer. After washing, SDS sample buffer was added and the samples were subjected to electrophoresis followed by Western blot. Biotinylated DNA used were the following: aRE, 5 0 -TATTGGCCAATA-3 0 ; control, 5 0 -AT ATCGCGATAT-3 0 .
ChIP assay
ChIP assay was performed with the ChIP assay kit (Upstate), according to the protocols provided by the manufacturer. Briefly, whole livers were dissected and homogenized, and cells were fixed with 1% formaldehyde for 10 min and sonicated in the SDS-lysis buffer (50 mM Tris-HCl (pH8.1), 10 mM EDTA, 1% SDS). Fragmented soluble chromatin was immunoprecipitated with antibodies. After washing, the precipitates were reverse crosslinked for DNA isolation and PCR analysis. PCR was performed with the following primers: PEPCK sense (À210), 5 0 -GAGGCCTCCCAACATTCAT-3 0 , antisense ( þ 67), 5 0 -CGCTGAGCGCCTTGCCGGA-3 0 ; b-actin sense (À75), 5 0 -GTTCCGAAAGTTGCCTTTTATG-3 0 , antisense ( þ 252), 5 0 -ATGTGGCTGCAAAGAGTCTACA-3 0 .
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
